Is it worth to apply extra-corporeal membrane oxygenation in the immunocompromised patients with severe acute respiratory distress syndrome?

Venous-venous extra-corporeal membrane oxygenation (VV-ECMO) is a recognized rescue therapy for severe acute respiratory distress syndrome (ARDS) in some reference’s centers around the world (1). VV-ECMO is usually applied when the ARDS patients achieve extremes of severe and life-threatening hypoxemia and hypercapnia during invasive mechanical ventilation that impairs the multidisciplinary team to mechanically ventilate these patients without exacerbating the risks of the mechanical ventilation induced lung injury (VILI) (1).